US15117B2025 - Common Stock
31.39 -0.28 (-0.88%)
CELLDEX THERAPEUTICS INC
NASDAQ:CLDX (12/6/2023, 12:06:48 PM)
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. The company is headquartered in Hampton, New Jersey and currently employs 148 full-time employees. The company is focused on developing therapeutic monoclonal and bispecific antibodies that address diseases for which available treatments are inadequate. Its drug candidates include antibody-based therapeutics, which has the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer. Its Barzolvolimab, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis and Eosinophilic Esophagitis. Its bispecific platform includes CDX-585 and CDX-527. CDX-585 combines its active PD-1 blockade and anti-ILT4 blockade to prevent immunosuppressive signals in T cells and myeloid cells, respectively. Its other programs include CDX-1140, a fully human agonist monoclonal antibody targeted to CD40.
CELLDEX THERAPEUTICS INC
53 Frontage Rd Ste 220
Hampton NEW JERSEY 08827
CEO: Anthony S. Marucci
HAMPTON, N.J., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside...
Are you looking for biotech breakthrough stocks? Here are three revolutionary stocks redefining healthcare.
Wells Fargo upgrades Celldex Therapeutics (CLDX) after Novartis' positive Phase 3 data for its tyrosine kinase inhibitor remibrutinib. Read more here.
Here you can normally see the latest stock twits on CLDX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.